Jennifer Condon
Family · Fort Dodge, IANPI 1386084747
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $18,657 of the $30,684 with a category attached, or 60.8%. 26 manufacturers reported payments, led by AstraZeneca at 45.6% of the total. Among family clinicians in IA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 162 payments — averaging $189.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$14K
- Boehringer Ingelheim$6K
- Sanofi$5K
- Mylan Specialty L.p.$3K
- ZOLL Respicardia, Inc.$2K
- Harmony Biosciences LLC$394
- plus $1K from 20 others
What the payments were for
- Consulting fees$4,84216%
- Speaking & faculty fees$18,65761%
- Travel & lodging$3,58412%
- Food & beverage$3,22010%
- Education$3811%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 31 | $14,000 |
| Boehringer Ingelheim | 30 | $5,972 |
| Sanofi | 15 | $5,059 |
| Mylan Specialty L.p. | 18 | $2,676 |
| ZOLL Respicardia, Inc. | 5 | $1,514 |
| Harmony Biosciences LLC | 7 | $394 |
| GSK | 19 | $215 |
| Jazz Pharmaceuticals Inc. | 6 | $166 |
| Sanofi-aventis U.S. LLC | 2 | $115 |
| Actelion Pharmaceuticals US, Inc. | 4 | $76 |
| Philips North America LLC | 3 | $65 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $49 |
| Pfizer | 2 | $44 |
| Abbott | 1 | $40 |
| Johnson & Johnson | 1 | $35 |
| Electromed, Inc. | 4 | $32 |
| Insmed, Inc. | 2 | $31 |
| Pulmonx Corporation | 1 | $29 |
| Inspire Medical Systems, Inc. | 1 | $28 |
| Amgen | 1 | $28 |
| Regeneron Healthcare Solutions, Inc. | 2 | $26 |
| United Therapeutics Corporation | 2 | $23 |
| Novo Nordisk | 1 | $19 |
| Baxter Healthcare | 1 | $19 |
| Axsome Therapeutics, Inc. | 1 | $17 |
| Advanced Respiratory, Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TEZSPIRE$13,573
- Yupelri$2,531
- DUPIXENT$1,523
- remede System$1,434
How this compares
$30,684 in reported general payments places this provider in the 95th percentile of 1,268 family providers in Iowa.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 906 | $672,928 |
| Dupixent PenDupilumab | 132 | $490,125 |
| Fasenra PenBenralizumab | 45 | $249,693 |
| WakixPitolisant Hcl | 19 | $232,339 |
| OpsumitMacitentan | 18 | $227,938 |
| Aralast NpAlpha-1-Proteinase Inhibitor | 12 | $194,972 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 272 | $187,996 |
| OfevNintedanib Esylate | 14 | $176,649 |
| Dupixent SyringeDupilumab | 38 | $143,417 |
| NucalaMepolizumab | 38 | $140,582 |
| TezspireTezepelumab-Ekko | 31 | $138,723 |
| Breo ElliptaFluticasone/Vilanterol | 235 | $121,137 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 103 | $53,399 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 76 | $52,409 |
| Spiriva RespimatTiotropium Bromide | 56 | $37,083 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta | $215 | $999,3271,313 claims |
| AstraZenecaBreztri Aerosphere, Tezspire, Symbicort | $14,000 | $354,633392 claims |
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat, Combivent Respimat | $5,972 | $278,560165 claims |
| Harmony Biosciences LLCWakix | $394 | $232,33919 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $76 | $227,93818 claims |
| Axsome Therapeutics, Inc.Sunosi | $17 | $29,98527 claims |
| PfizerEliquis | $44 | $28,10741 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,268 family providers in Iowa.
Other family in Fort Dodge
- Joan KittenFort Dodge$85K
- Kathryn FoyFort Dodge$5K
- Stefanie GaticaAnkeny$354K
- Aubrey MolgaardAmes$238K
- Megan FergusonPella$82K
- Rodney ClarkDes Moines$63K
- Karen HunkeAmes$20K
- Tonia AckermanWest Des Moines$17K
- Chi-Ying SageWaterloo$14K
- Amanda GaldiNorth Liberty$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.